Results 71 to 80 of about 9,247 (168)

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

American Journal of Hematology, Volume 101, Issue 8, Page 1903-1914, August 2026.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt, Ute Hegenbart, Tamer Hellou, Sara Oubari, Murielle Roussel, Rahel Schwotzer, Francis Buadi, David Dingli, Moritz Binder, Taxiarchis Kourelis, Saurabh S. Zanwar, Max J. Rieger, Caroline Morbach, Vladimir Cejka, Bernhard Gerber, Stefan Störk, Hermann Einsele, Shaji Kumar, Morie Gertz, Alexander Carpinteiro, K. Martin Kortum, Eli Muchtar, Angela Dispenzieri, Stefan Schönland   +23 more
wiley   +1 more source

Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents‐Based Induction Therapy

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Extramedullary disease (EMD) in newly diagnosed multiple myeloma (NDMM) is aggressive and associated with worse survival. This study aimed to comprehensively evaluate the clinical outcomes and factors affecting prognosis in NDMM patients with EMD receiving novel agents‐based induction therapy.
Xiaoxi Xu, Yiru Wang, Wenhuan Zhang, Xin Liu, Luqun Wang, Jun Peng, Ming Hou, Hai Zhou   +7 more
wiley   +1 more source

Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Yixuan Chen, Wenming Huang, Mingxuan Tang, Xiaotao Wang   +3 more
wiley   +1 more source

Temperature Safeguards and Peri‐Procedural Strategies for Stem Cell Collection in Cold Agglutinin Disease: A Case Report and Literature Review

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Cold agglutinins can result in red blood cell (RBC) agglutination and lysis at low temperatures. Temperature sensitivity during stem cell mobilization, processing, and infusion poses unique procedural challenges in patients with active cold agglutinins.
S. Bellegarde, C. Scott, R. Sabol, T. Eunson, Z. J. Gahvari, C. P. Onyenekwu   +5 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Immune Effector Cell‐Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene‐Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Pancytopenia accompanied by chimeric antigen receptor T cell (CAR‐T) therapy is termed immune effector cell‐associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52‐year‐old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after ...
Keishi Ogura, Takahiro Fujino, Takahisa Nakamura, Akihiro Miyashita, Akio Onishi, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shinichi Fuchida, Junya Kuroda   +9 more
wiley   +1 more source

Successful Bortezomib–Lenalidomide–Dexamethasone Therapy in a 72‐Year‐Old Patient With Sporadic Late‐Onset Nemaline Myopathy Associated With Monoclonal Gammopathy of Muscle Significance

Muscle &Nerve, Volume 74, Issue 3, Page 756-758, September 2026.
Hiroki Komatsu, Shogo Komaki, Meiko Maeda, Akatsuki Kubota, Mitsuhiro Yuasa, Mineo Kurokawa, Ryo Morishima, Satoko Uruha, Akinori Uruha, Ichizo Nishino, Masashi Hamada, Tatsushi Toda, Wataru Satake   +12 more
wiley   +1 more source

Real‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. Aims To evaluate treatment patterns and identify unmet clinical needs in RRMM across Italian hematology centers.
Francesca Fazio, Alfonso Piciocchi, Paolo de Fabritiis, Messina Messina, Stefano Soddu, Valeria Sargentini, Francesco Di Raimondo, Francesca Patriarca, Pellegrino Musto, Maurizio Offidani, Elena Zamagni, Sara Bringhen, Massimo Gentile, Giuseppe Mele, Paola Fazi, MariaTeresa Petrucci, Michele Cavo   +16 more
wiley   +1 more source

Efficacy and Safety of Daratumumab‐Based Regimens in Multiple Myeloma: A Systematic Review and Meta‐Analysis of Phase III Randomized Controlled Trials

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Multiple myeloma is a malignant plasma cell disorder predominantly affecting older adults and poses a significant health burden due to its incurable nature, high relapse rate, and associated immune dysfunction. Daratumumab, when added to standard therapy, has shown promising results in large trials.
Abdul Moiz Khan, Hafsa Ajmal, Muddassir Khalid, Waleed Babar, Usama Shafaqat, Tooba Fida, Mohammad Aitzaz Hassan, Sibgha Fatima, Ahmad Sameed Akram, Fred Segawa   +9 more
wiley   +1 more source

Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection‐related mortality remains a significant concern for patients' overall survival (OS). Methods This Swedish, population‐based study examined incidence of infections and OS in
Ingrid Glimelius, Love Tätting, Jonatan Freilich, M. Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurður Y. Kristinsson   +6 more
wiley   +1 more source